# EDGAR Filing Document

**Accession Number:** 0001873093
**File Stem:** 0001641172-25-020369
**Filing Date:** 2025-7
**Character Count:** 8511
**Document Hash:** 1979c7e7f2e1db7e12d7d5106d5a6ac5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-020369.hdr.sgml**: 20250721

**ACCESSION NUMBER**: 0001641172-25-020369

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250721

**FILED AS OF DATE**: 20250721

**DATE AS OF CHANGE**: 20250721

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CytoMed Therapeutics Ltd
- **CENTRAL INDEX KEY:** 0001873093
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** U0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41677
- **FILM NUMBER:** 251136003

**BUSINESS ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544
- **BUSINESS PHONE:** 603824911

**MAIL ADDRESS:**
- **STREET 1:** #08-22 ONE COMMONWEALTH
- **CITY:** 1 COMMONWEALTH LANE
- **STATE:** U0
- **ZIP:** 149544

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CytoMed Therapeutics Pte. Ltd.
- **DATE OF NAME CHANGE:** 20210716

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of July 2025

**Commission File Number: 001-41677**

**CytoMed Therapeutics Limited**

(Exact name of registrant as specified in its charter)

**1 Commonwealth Lane**

**#08-22**

**Singapore 149544**

**(Address of Principal Executive Office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**INFORMATION CONTAINED IN THIS FORM 6-K REPORT**

On July 21, 2025, CytoMed Therapeutics Limited (the "Company") issued a press release announcing that the Company has completed Dose Level 1 of its first-in-human Phase I dose-escalation clinical trial of CTM-N2D ("ANGELICA Trial"), and is proceeding to Dose Level 2.

A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

**Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release dated July 21, 2025 titled: Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies](ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CytoMed Therapeutics Limited** | **CytoMed Therapeutics Limited** |
| Date: July 21, 2025 | By: | */s/ CHOO Chee Kong* |
|  |  | CHOO Chee Kong<br> Director and Chairman |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies**

**SINGAPORE, July 21, 2025 —** Further to our <u>announcement filed on Form 6-K on November 20, 2024</u>, <u>CytoMed Therapeutics Limited</u> (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce the successful completion of dose level 1 for its first-in-human Phase I dose-escalation clinical trial (<u>NCT05302037</u>) ("ANGELICA Trial") for four late stage cancer patients and is scheduled to start dose level 2 of the ANGELICA Trial in third quarter of 2025.

The ANGELICA Trial evaluates the safety and tolerability of allogeneic NKG2DL-targeting chimeric antigen receptor-grafted (CAR) gamma delta T cells (CTM-N2D) in the treatment of a basket of cancer indications that include advanced solid and haematological malignancies. Refer to our announcement on <u>Form 6K on October 7, 2024</u> for more information regarding the ANGELICA Trial.

CTM-N2D uses a subtype of T cells known as gamma delta T cells which are derived from healthy donors, which are expanded and modified to express CAR that targets NKG2DL that are commonly present in many cancers. CTM-N2D can be infused into patients without the need for donor-patient compatibility matching.

This differs from conventional CAR-αβ T cell therapies that typically involve the collection of patient's own blood cells and modifying these cells to express cancer-targeting CARs. The modified αβ T cells are then re-infused back into the patient to target and kill cancer cells. Unlike chemotherapy that targets all actively dividing cells including healthy ones, CAR-T cells specifically recognize targets (antigen) present on cancer cells to kill them.

**About CytoMed Therapeutics Limited (CytoMed)**

Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A\*STAR), Singapore's leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit <u>www.cytomed.sg</u> and follow us on Twitter ("X") <u>@CytomedSG</u>,on <u>LinkedIn</u>, and <u>Facebook</u>

**Forward-Looking Statements**

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

**Contact :**

**CytoMed Therapeutics Limited**

enquiry@cytomed.sg

Attention : Evelyn Tan, Chief Corporate Officer